catheter system News
-
Moray Medical named a Rosenman Innovator
An esteemed panel of subject matter experts, clinicians, and investors selected Moray Medical (then called Project Moray) as a Rosenman Innovator for its innovative technology and patient impact, digitizing the user interface of cardiac catheter systems to enable precise delivery of therapies within the beating hearts of millions of patients. The UCSF Rosenman Institute, a health technology ...
-
Q’Apel Medical Welcomes Jodie Fam, Vice President and General Manager, International
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Jodie Fam as Vice President and General Manager, International. Jodie will be responsible for the leadership and development of International Sales for Q’Apel. Jodie brings more than 20 ...
-
Q’Apel Medical Welcomes Thomas Berryman, Chief Financial Officer
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Thomas Berryman as Chief Financial Officer. Tom has extensive experience in bringing venture funded medical technology companies from initial startup through product commercialization, revenue ...
-
Bluegrass Vascular Technologies Announces Publication of Surfacer System IDE Study Results
Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of the results of its prospective, multicenter SAVE-US (Surfacer® System to Facilitate Access in VEnous Occlusions – United States) study in the Journal of Vascular Access. This ...
-
Bluegrass Vascular Announces Publication of Surfacer System SAVE Registry Results
Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of the results from the company’s prospective, multicenter SAVE (Surfacer® System to Facilitate Access in VEnous Occlusions) Registry in the Journal of Vascular and Interventional ...
-
Infuseon Therapeutics, Inc. CMO Discusses Delivery of Therapeutics Directly to the Brain at NeuroTech Investing and Partnering Conference
infuseon therapeutics, Inc., the company that enables therapeutic delivery to the brain, announces that Dr. Michael A. Vogelbaum, Chief Medical Officer and co-inventor of the Cleveland Multiport Catheter system, will be speaking at the NeuroTech Investing and Partnering Conference taking place in Boston on Thursday, April 7. Dr. Vogelbaum, a brain surgeon at Cleveland Clinic, will be part of the ...
-
Q’Apel Medical Announces Move to New Headquarters Facility in Fremont, CA
New 35,000 square foot Facility will support the company’s growth and OUS expansion Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today that it will relocate its existing headquarters into a new building at 4245 Technology Dr, Fremont, CA, 94538. The 35,000 ...
-
Bluegrass Vascular Announces Publication Reporting Long-term data following facilitation of HeRO graft placement using the Surfacer System
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report three cases where the Surfacer System was used to help facilitate the placement of the HeRO graft in patients with thoracic central venous obstruction (TCVO) where other methods for crossing the ...
-
Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies
Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise On Thursday, the company entered a trading halt, pausing shares until Monday, August 2 It is unknown how much the company is planning to raise or where the funds will be spent On the market, Anteris last traded at $8.59 per share Anteris Technologies (AVR) has paused trading as it plans for an upcoming ...
-
Q’Apel Medical Raises $22 Million to Grow Highly Innovative Neurovascular Access Platform & Scott Huennekens joins Board of Directors.
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. The round included River Cities Capital, Soleus Capital and incumbent investor, Research Corporation Technologies (RCT). Scott Huennekens, former Chairman, CEO and ...
-
Bluegrass Vascular Closes $5 Million Convertible Debt Financing
Privately held Bluegrass Vascular Technologies, a leading innovator and global manufacturer of lifesaving devices and methods based on the Inside-Out® vascular access procedure, today announced the closing of a $5.0 million financing in convertible promissory notes to a group of qualified investors, including new investors and existing shareholders who participated in previous capital raises. ...
-
Galaxy Medical Enrolls First Patients in SPACE-AF Study SAN
SAN CARLOS, California, September 20, 2021 — Galaxy Medical announced today the initiation of the SPACE-AF study with enrollment of the first two patients at Southlake Regional Health Centre in Newmarket, Canada. In the study, the CENTAURI Pulsed Electric Field (PEF) ablation system will be used to ablate both the pulmonary veins and posterior walls in patients with persistent atrial ...
-
Bluegrass Vascular Announces Decision by Medicare to Assign a New Technology Ambulatory Payment Classification (APC) for the Surfacer System Procedure
Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that the Centers for Medicare & Medicaid Services (CMS) has finalized a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment Classification (APC) assignment ...
-
Bluegrass Vascular Announces New Paper Reporting Ability to Eliminate Use of a Femoral Catheter with the Surfacer System
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a case report demonstrating the ability to utilize the Surfacer® System to perform the Inside-Out® procedure and obtain right-sided central venous access in a patient with central venous occlusion and ...
-
Sofregen Receives 510(k) Clearance for Silk Voice - The First and Only Natural Silk Protein Injectable Product for Tissue Bulking
Sofregen Medical, Inc. (Sofregen), an early stage commercial biotechnology company developing products for medical aesthetics and reconstructive surgery, announced today that Silk Voice has been cleared by the U.S. Food and Drug Administration (FDA) for augmenting vocal fold tissue for phonation improvement. This is the first and only FDA cleared product made from solubilized silk protein and is ...
-
Galaxy Medical and Japan Lifeline Enter Distribution Agreement for Novel Pulsed Electric Field Focal Ablation Catheter
SAN CARLOS, California, April 6, 2021 — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. Under the terms of the agreement, Galaxy will pursue US regulatory approval for ALPHA1 in ...
-
Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally. The AcQForce Flutter trial was designed to ...
-
Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System
VANCOUVER, British Columbia – Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System. The Globe System is the most complete solution for the treatment of atrial fibrillation (AF) – the world’s most common heart rhythm disorder, affecting more than 37 million people. The first patients were treated in Europe. During the last few weeks, ...
By Kardium Inc.
-
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and mapping systems from Boston ...
-
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
GALAXY’S PROPRIETARY CENTAURI™ SYSTEM ON TRACK FOR EU REGISTRATION AND US PIVOTAL TRIAL START LATER THIS YEAR; SHOWS BEST-IN-CLASS POTENTIAL. SAN CARLOS, California, March 16, 2021 — ATP, a leader in life science venture capital, announced today $18M in Series A financing for its portfolio company Galaxy Medical, Inc. The funds are being used to advance the development of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you